CS Tam
9 Papers
1 Citations
CS Tam is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 7 publications.
Chat about Author
Papers
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria.
SP Treon,Alessandra Tedeschi,J. San-Miguel,Ramón García-Sanz,KC Anderson,Eva Kimby,Giulia Benevolo,Lin Qiu,S. Yi,Evangelos Terpos,CS Tam,JJ Onofre – Castillo,P. Morel,M.A. Dimopoulos,R. G. Owen +14 more
TL;DR: Consensus Panel 4 (CP4) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with reviewing the current criteria for diagnosis and response assessment as mentioned in this paper .
21
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY
Mazyar Shadman,Tal Munir,T Roback,J. Brown,Brad S. Kahl,Paolo Ghia,Krzysztof Giannopoulos,Martin Simkovic,Anders Österborg,Luca Laurenti,Patricia F. Walker,Stephen Opat,Hanna Ciepluch,Richard Greil,Michelle Hanna,Monica Tani,Marek Trneny,Danielle M. Brander,Ian W. Flinn,Sebastian Grosicki,Emma Verner,Alessandra Tedeschi,Sophie de Guibert,Gayane Tumyan,Kamel Laribi,J.A. Meana García,J. Li,T. Tian,V Ramakrishnan,Yi Liu,A. Szeto,Jee Paik,Aileen C. Cohen,CS Tam,Woijciech Jurczak +34 more
5
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.
Shirley D'Sa,Ranjana H. Advani,Christian Buske,JJ Onofre – Castillo,Marise Gatt,P. Kapoor,MJ Kersten,Véronique Leblond,Merav Leiba,ML Palomba,Jonas Paludo,Lin Qiu,Shayna Sarosiek,Mayzar Shadman,CS Tam,Alessandra Tedeschi,S. Thomas,Ibrahim Tohidi-Esfahani,Judith Trotman,Marzia Varettoni,Jmi Vos,Ramón García-Sanz,J. San-Miguel,M.A. Dimopoulos,SP Treon,Efsthathios Kastritis +25 more
TL;DR: The consensus panel of the 11th International Workshop on Waldenström's macroglobulinemia (IWWM-11) as mentioned in this paper reviewed and incorporated current data to update the recommendations for treatment approaches in patients with relapsed or refractory WM (RRWM).
5
Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Impact on health‐related quality of life
Barbara Eichhorst,E. Lamanna,Shannon M. O'Brien,CS Tam,Lugui Qiu,K. Yang,Ken Wu,Tommi Salmi,Gisoo Barnes,J. Brown +9 more
TL;DR: Zanubrutinib (zanu) is a next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target effects as mentioned in this paper .
1
Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety database
J. Brown,Barbara Eichorst,Paolo Ghia,Woijciech Jurczak,Brad S. Kahl,E. Lamanna,Tadeusz Robak,Mazyar Shadman,CS Tam,Lugui Qiu,Aileen C. Cohen,Jinghui Zhang,Tommi Salmi,Jason C. Paik,L. M. Wang,J. Y. Zhang,H. Ma,Alessandra Tedeschi +17 more
TL;DR: In this article , the authors characterized the overall safety/tolerability of zanu and compared it with ibr in patients (pts) with B-cell malignancies using the zanu clinical safety database.